Icahn Appointees' Board Exit Might Change The Case For Investing In Bausch Health Companies (BHC)

• On August 14, 2025, Brett M. Icahn and Steven D. Miller, both appointees of the Icahn Group, resigned from Bausch Health Companies' board of directors after the termination of the Appointment and Nomination Agreement.
• This development marks a significant shift in the company's corporate governance and may influence investor perspectives on board oversight and future direction.
• We'll examine how the simultaneous departure of two Icahn Group board members could influence Bausch Health Companies' investment outlook.

We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Bausch Health Companies Investment Narrative Recap

To own shares in Bausch Health Companies, investors need to believe in the company’s ability to drive revenue growth from key products in gastroenterology, navigate upcoming regulatory challenges, and manage its high debt load. The recent resignation of two Icahn Group appointees from the board appears not to materially impact the short-term catalyst, namely expanding into new therapeutic areas, nor does it significantly shift the immediate risk, which remains concentrated around future Xifaxan price negotiations and heavy leverage.

Against this backdrop, Bausch recently raised its 2025 revenue guidance to US$10.0–10.25 billion, up from earlier projections, citing resilient product demand. While this outlook supports the view that core growth drivers remain on track, the loss of board expertise linked to oversight could still be relevant if governance concerns emerge during critical phases such as debt refinancing or product launches.

Yet, if broader regulatory risks intensify or board stability wavers, investors should also be aware that...

Read the full narrative on Bausch Health Companies (it's free!)

Bausch Health Companies is projected to reach $10.1 billion in revenue and $264.4 million in earnings by 2028. This outlook assumes a 0.9% annual decline in revenue and an earnings increase of $166.4 million from the current $98.0 million.

Uncover how Bausch Health Companies' forecasts yield a $7.08 fair value, a 3% downside to its current price.

Exploring Other Perspectives

Five valuations from the Simply Wall St Community put Bausch Health’s fair value between US$7.08 and US$64.84 per share. With such a wide span in estimates, consider how execution on new product launches and forward-looking risks may drive sharply different outcomes for shareholders.

Explore 5 other fair value estimates on Bausch Health Companies - why the stock might be worth just $7.08!

Build Your Own Bausch Health Companies Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Bausch Health Companies research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Bausch Health Companies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bausch Health Companies' overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• Find companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com